Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
AssigneeBiPar Sciences, Inc.
InventorsBarry M. Sherman, Charles Bradley, Valeria Ossovskaya
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
Claims147
A method of treating uterine cancer or ovarian cancer in a patient, comprising administering to the patient at least one PARP inhibitor.
A method of treating ovarian cancer or uterine cancer in a patient in need of such treatment, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine whether the patient is BRCA deficient;
- (c) if the testing indicates that the patient is BRCA-deficient, treating the patient with at least one PARP inhibitor.
A method of treating ovarian cancer or uterine cancer in a patient in need of such treatment, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine a level of PARP expression in the sample;
- (c) determining whether the PARP expression exceeds a predetermined level, and if so, administering to the patient at least one PARP inhibitor.
A method of treating uterine cancer or ovarian cancer in a patient, comprising administering to the patient a combination of at least one PARP inhibitor and at least one anti-tumor agent.
A method of treating ovarian cancer or uterine cancer in a patient in need of such treatment, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine whether the patient is BRCA deficient;
- (c) if the testing indicates that the patient is BRCA-deficient, treating the patient with at least one PARP inhibitor and at least one anti-tumor agent.
A method of treating uterine cancer or ovarian cancer in a patient, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine a level of PARP expression in the sample;
- (c) determining whether the PARP expression exceeds a predetermined level, and if so, administering to the patient at least one PARP inhibitor and at least one anti-tumor agent.
Dependencies are inferred from the claim text.